[go: up one dir, main page]

NO20025811L - Forbindelser som er effektive som beta-2-adrenoreseptor- agonister så vel som PDE4-inhibitorer - Google Patents

Forbindelser som er effektive som beta-2-adrenoreseptor- agonister så vel som PDE4-inhibitorer

Info

Publication number
NO20025811L
NO20025811L NO20025811A NO20025811A NO20025811L NO 20025811 L NO20025811 L NO 20025811L NO 20025811 A NO20025811 A NO 20025811A NO 20025811 A NO20025811 A NO 20025811A NO 20025811 L NO20025811 L NO 20025811L
Authority
NO
Norway
Prior art keywords
beta
well
pde4 inhibitors
adrenoceptor agonists
compounds effective
Prior art date
Application number
NO20025811A
Other languages
English (en)
Other versions
NO20025811D0 (no
Inventor
Armin Hatzelmann
Daniela Bundschuh
Manfrid Eltze
Geert Jan Sterk
Yvonne Johanna Van Der Laan
Hendrik Timmermann
Johannes A M Christiaans
Paulus Johannes Gaurer Brundel
Original Assignee
Altana Pharma Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altana Pharma Bv filed Critical Altana Pharma Bv
Publication of NO20025811D0 publication Critical patent/NO20025811D0/no
Publication of NO20025811L publication Critical patent/NO20025811L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Forbindelsene med formel I. i hvilke Ari, A, R6, R7, R8, og Arhar betydningene som er angitt i beskrivelsen, er nye effektive bronkialterapeutika.
NO20025811A 2000-06-05 2002-12-03 Forbindelser som er effektive som beta-2-adrenoreseptor- agonister så vel som PDE4-inhibitorer NO20025811L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00111795 2000-06-05
PCT/EP2001/006230 WO2001094319A1 (en) 2000-06-05 2001-06-01 Compounds effective as beta-2-adrenoreceptor agonists as well as pde4-inhibitors

Publications (2)

Publication Number Publication Date
NO20025811D0 NO20025811D0 (no) 2002-12-03
NO20025811L true NO20025811L (no) 2003-02-04

Family

ID=8168897

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20025811A NO20025811L (no) 2000-06-05 2002-12-03 Forbindelser som er effektive som beta-2-adrenoreseptor- agonister så vel som PDE4-inhibitorer

Country Status (20)

Country Link
US (1) US6933296B2 (no)
EP (1) EP1296956A1 (no)
JP (1) JP2003535850A (no)
KR (1) KR20030031907A (no)
CN (1) CN1471515A (no)
AU (2) AU2001262332B2 (no)
BR (1) BR0111440A (no)
CA (1) CA2411351A1 (no)
CZ (1) CZ20023997A3 (no)
EA (1) EA005824B1 (no)
HK (1) HK1052346A1 (no)
HU (1) HUP0301240A3 (no)
IL (1) IL152846A0 (no)
MX (1) MXPA02012042A (no)
NO (1) NO20025811L (no)
NZ (1) NZ522882A (no)
PL (1) PL358057A1 (no)
SK (1) SK17052002A3 (no)
WO (1) WO2001094319A1 (no)
ZA (1) ZA200209598B (no)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0303193A3 (en) 2001-02-15 2007-08-28 Altana Pharma Ag Phthalayinone-piperidino-derivatives as pde4 inhibitors and pharmaceutical compositions containing them
US7186710B2 (en) 2001-04-25 2007-03-06 Altana Pharma Ag Phthalazinones
CZ20033205A3 (en) 2001-04-25 2004-03-17 Altana Pharma Ag Piperazino-derivatives and their use as pde4 inhibitor
ES2195785B1 (es) 2002-05-16 2005-03-16 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
HRP20050197A2 (en) * 2002-08-10 2006-06-30 Altana Pharma Ag Piperidine-n-oxide-derivatives
CA2494613C (en) * 2002-08-10 2011-06-28 Altana Pharma Ag Pyrrolidinedione substituted piperidine-phthalazones as pde4 inhibitors
EP1556369A1 (en) * 2002-08-10 2005-07-27 ALTANA Pharma AG Pyridazinone-derivatives as pde4 inhibitors
WO2004058726A2 (en) * 2002-12-23 2004-07-15 Artesian Therapeutics, Inc. CARDIOTONIC COMPOUNDS WITH INHIBITORY ACTIVITY AGAINST β-ADRENERGIC RECEPTORS AND PHOSPHODIESTERASE
ES2211344B1 (es) * 2002-12-26 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
ES2232306B1 (es) 2003-11-10 2006-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
WO2005075437A1 (en) * 2004-02-04 2005-08-18 Altana Pharma Ag Pyridazinone derivatives and their use as pde4 inhibitors
CA2554797C (en) 2004-02-04 2012-09-04 Altana Pharma Ag 2-(piperidin-4-yl)-4,5-dihydro-2h-pyridazin-3-one derivatives as pde4 inhibitors
ES2251866B1 (es) 2004-06-18 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
RU2008122978A (ru) 2005-11-09 2009-12-20 Комбинаторкс, Инкорпорейтед (Us) Способы, композиции и наборы для лечения медицинских состояний
GB0602778D0 (en) 2006-02-10 2006-03-22 Glaxo Group Ltd Novel compound
GB0805535D0 (en) 2008-03-27 2008-04-30 Univ Leicester Scar prevention
CA2733128C (en) 2008-08-13 2016-05-24 Boehringer Ingelheim International Gmbh Phthalazinone compounds as chymase inhibitors
US8367829B2 (en) 2010-05-10 2013-02-05 Gilead Sciences, Inc. Bi-functional pyrazolopyridine compounds
JP5807058B2 (ja) * 2010-05-10 2015-11-10 ギリアード サイエンシーズ， インコーポレイテッド 二機能キノリン誘導体
PH12013502546A1 (en) * 2011-06-17 2014-01-27 Takeda Gmbh Novel phthalazinone-pyrrolopyrimidinecarboxamide derivatives
US20150119399A1 (en) 2012-01-10 2015-04-30 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
GB2513297A (en) 2013-03-08 2014-10-29 Univ Leicester Methods
EA202191084A1 (ru) 2018-11-06 2021-10-19 Эджвайз Терапьютикс, Инк. Соединения пиридазинонов и их применения
ES2957383T3 (es) 2018-11-06 2024-01-18 Edgewise Therapeutics Inc Compuestos de piridazinona y usos de estos
JP7671245B2 (ja) 2018-11-06 2025-05-01 エッジワイズ セラピューティクス， インコーポレイテッド ピリダジノン化合物およびその使用
EP4149621B1 (en) * 2020-05-13 2024-10-30 Edgewise Therapeutics, Inc. Pyridazinone compounds for the treatment of neuromuscular diseases

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3063196D1 (en) * 1979-12-05 1983-06-16 Morishita Pharma Derivatives of 2-substituted-6-phenyl-3(2h)pyridazinone, their production and pharmaceutical compositions containing them
JPS58146571A (ja) * 1982-02-25 1983-09-01 Morishita Seiyaku Kk ウレア誘導体およびその製造法
PL164079B1 (pl) * 1990-06-15 1994-06-30 Akad Medyczna posób wytwarzania nowych 2-amlnoalkilopochodnych 5-aminometyleno-6-/p-chlorofenylo /-4,5-dihydro-2H- plrydazyn -3-onu
JP3100984B2 (ja) 1992-12-02 2000-10-23 ファイザー・インク． 選択的ｐｄｅ▲下ｉ▼▲下ｖ▼阻害物質としてのカテコールジエーテル類
DE19533975A1 (de) 1995-09-14 1997-03-20 Merck Patent Gmbh Arylalkyl-diazinone
SK283270B6 (sk) 1997-01-15 2003-04-01 Altana Pharma Ag Ftalazinóny, farmaceutické prostriedky s ich obsahom a ich použitie
DE59814173D1 (de) 1997-02-28 2008-04-03 Nycomed Gmbh Synergistische kombination von pde-hemmern und adenylatcyclase-agonisten bzw. guanylcyclyse-agonisten
PT1042319E (pt) 1997-12-15 2004-06-30 Altana Pharma Ag Di-hidro-benzofuranos
WO1999031071A1 (en) 1997-12-15 1999-06-24 Byk Gulden Lomberg Chemische Fabrik Gmbh New phthalazinones
EP0934933A1 (en) 1998-02-06 1999-08-11 Byk Gulden Lomberg Chemische Fabrik GmbH Phthalazinones
US6288118B1 (en) 1998-08-26 2001-09-11 Smithkline Beecham Corporation Therapies for treating pulmonary diseases

Also Published As

Publication number Publication date
JP2003535850A (ja) 2003-12-02
US6933296B2 (en) 2005-08-23
CN1471515A (zh) 2004-01-28
SK17052002A3 (sk) 2003-12-02
PL358057A1 (en) 2004-08-09
EA200201252A1 (ru) 2003-06-26
HK1052346A1 (zh) 2003-09-11
NO20025811D0 (no) 2002-12-03
BR0111440A (pt) 2003-06-03
NZ522882A (en) 2004-07-30
EP1296956A1 (en) 2003-04-02
HUP0301240A2 (hu) 2003-12-29
WO2001094319A1 (en) 2001-12-13
KR20030031907A (ko) 2003-04-23
MXPA02012042A (es) 2004-08-19
AU6233201A (en) 2001-12-17
ZA200209598B (en) 2003-07-29
IL152846A0 (en) 2003-06-24
US20030195215A1 (en) 2003-10-16
CZ20023997A3 (cs) 2003-05-14
AU2001262332B2 (en) 2006-05-25
HUP0301240A3 (en) 2004-03-29
EA005824B1 (ru) 2005-06-30
CA2411351A1 (en) 2001-12-13

Similar Documents

Publication Publication Date Title
NO20025811L (no) Forbindelser som er effektive som beta-2-adrenoreseptor- agonister så vel som PDE4-inhibitorer
IS7721A (is) Píperidín-pýrídasón og þalasón sem PDE4 hemlar
ATE348616T1 (de) 2-hydroxy-6-phenylphenanthridine als pde-4-hemmer
ATE353217T1 (de) 3-hydroxy-6-phenylphenanthridine als pde-4 inhibitoren
BRPI0608886B8 (pt) derivados de n-sulfonilpirróis e seus usos
NO20070532L (no) Substituerte 2-alkyl-kinazolinonderivater som PARP-inhibitorer
NO20071593L (no) Pyrimidinderivater
NO20051082L (no) Antimikrobielle kinoloner, deres sammensetninger og anvendelser
DE60334536D1 (de) Furylverbindungen
DE60112306D1 (de) Kondensierte pyrazindionderivate als pde5 inhibitore
PE20030061A1 (es) 1-biaril-1,8-naftiridin-4-ona como inhibidores de fosfodiesterasa-4
DE60313350D1 (de) Pyrimidin-2,4-dion-derivate als matrix-metalloproteinase-hemmer
NO20062021L (no) Omleirede pentanoler, fremgangsmpte for fremstilling av dette, og deres anvendelse som antiflogistika
TW200600499A (en) Novel amido-substituted hydroxy-6-phenylphenanthridines
ATE333457T1 (de) Zyklische gmp-spezifische phosphodiesteraseinhibitoren
ATE359283T1 (de) Substituierte pyrazinonverbindungen zur behandlung von entzündungen
NO20015892D0 (no) Inhibitorer av metallproteinaser
DE60122559D1 (de) Indolderivate als pde5-inhibitoren
NO20023951L (no) Arylpiperaziner og arylpiperidiner og deres anvendelse som metalloproteinaseinhiberende midler
DE60110124D1 (de) Kondensierte pyrazindionderivate als pde inhibitoren
EA200301101A1 (ru) Производные пиперазина и их применение в качестве ингибиторов pde4
NO20064491L (no) Nye difluomtoksysubstituee hydroksy-6-fenylfenantridiner og deres anvendelse som PDE4-inhibitorer
NO20064417L (no) Nye isoamidosubstituertehydroksy-6-fenylfenantridiner
ATE480519T1 (de) Piperidinderivate als prodrugs von kaliumkanalinhibitoren
PT1276722E (pt) Inibidores de naftamidina-uroquinase

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application